Anti-Rheumatic Rx
![](https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg)
3 years 3 months ago
Video: Prevalence of Long Term HCQ in Retinal Toxicity: Dr. Kathryn Dao (@KDAO2011 )
Dr. Kathryn Dao reviews abstract OP0133, "The Prevalence and Risk Factors of Retinal Toxicity Associated with Long-Term Hydroxychloroquine Use", presented at #EULAR2021.
https://t.co/tZyXQhZgLG https://t.co/x6AfItFWEU
![](https://pbs.twimg.com/media/E3ScEgbXoAMfAaV.jpg)
![](https://pbs.twimg.com/profile_images/1324821320429981703/dAiq_hpT.jpg)
3 years 3 months ago
Excellent talk on SLE, APS abs pregancy
⭐️pregnancy counseling is important
⭐️aspirin 81mg in all pregnant SLE pts
⭐️do not discontinue HCQ
⭐️stable LN - can switch MMF to AZA
Abs#6888
#EULAR2021 @RheumNow
![](https://pbs.twimg.com/profile_images/1373134367841681415/ThbCOjtj.jpg)
3 years 3 months ago
On choosing an agent for MTX-IR RA:
"(at the end of talk) My short answer could have been... there's no right or wrong. It's still one of the dilemmas we have in the treatment of RA: choosing the right drug for the right patient" - @DanielAletaha
#EULAR2021 @RheumNow https://t.co/C45ey1SrA1
![](https://pbs.twimg.com/media/E3HMXQVVcAUSNe8.jpg)
![](https://pbs.twimg.com/profile_images/1146674086225035265/U4xc4Mka.jpg)
3 years 3 months ago
@DanielAletaha @RheumNow In the end the best treatment choice after #MTX insufficient responders not yet clear.
Head to head JAK-i vs. non-TNFi interesting
Brilliant developing discussion
number needed to harm vs. number needed to treat
#EULAR2021 @RheumNow
![](https://pbs.twimg.com/profile_images/881667486353154048/E6wDA0tb.jpg)
3 years 3 months ago
Results: MTX vs. PBO
✅Difference in least-squares mean ΔeGFR 0.93 mL/min/1.73m2 (p<0.001)
✅HR for kidney AE on safety labs: 0.73 (0.59-0.91)
✔️HR for kidney AE clinical events: 0.87 (0.56-1.36)
✔️4 vs. 8 severe kidney AEs (HR 0.50, 0.15-1.64)
![](https://pbs.twimg.com/profile_images/847812732007133184/hIbnEHt3.jpg)
3 years 3 months ago
HUR-BIO real life data, PsA pts started bDMARDs w/in 18 mo of dx vs almost 3x later in RA pts (tended to remain on csDMARDs.) This distinction may be explained by synthetic DMARDs on activity differences between the RA & PsA. Abstract #POS0633 #EULAR2021 https://t.co/VkkF28jm2f https://t.co/IkfGdZYNY3
![](https://pbs.twimg.com/media/E3HzrDCX0AIFF4r.jpg)
![](https://pbs.twimg.com/profile_images/881667486353154048/E6wDA0tb.jpg)
3 years 3 months ago
🤜MTX safe from kidney perspective if baseline CrCl 40+
🤜Potential for immunomodulation to prevent/slow progression to CKD? Deserves dedicated studies @Nephro_Sparks
![](https://pbs.twimg.com/profile_images/917734279056187392/qbUrlWGG.jpg)
3 years 3 months ago
Which biomarkers could guide csDMARDs tapering in #RA patients in #remission? Dr Gul reported in a cohort study using a tapering protocol, 35% had relapsed. Risk score for sustained remission comprise IRC<2%, MSK-US PD=0 and RAQoL=<1 (AUC=0.89) #EULAR2021 #OP0182 @RheumNow https://t.co/y1Y6ug7f3w
![](https://pbs.twimg.com/media/E3IDLfXWUAIVBNl.png)
![](https://pbs.twimg.com/profile_images/881667486353154048/E6wDA0tb.jpg)
3 years 3 months ago
How does MTX affect kidney function/adverse events? Pre-specified analysis of DBRCT: MTX 15-20mg/wk (n=2391) vs. PBO (n=2395) both with folic acid over median f/u 23 months
✅We demonstrated kidney safety of MTX
⚡️⚡️Also a *suggestion* of LESS decline in eGFR for MTX than PBO https://t.co/SZXloLRmnj